These results correlate well with those obtained in behavioral studies, in which we showed for the first time that the administration of neutralizing antibodies for CCL3 and CCL9 showed analgesic effects on Day 7 in CCI-evoked neuropathy. The gene discussed is CCL3; the disease is neuropathy.